After DNA replication, chromosomal processes including DNA repair and transcription take place in the context of sister chromatids. While cell cycle regulation can guide these processes globally, mechanisms to distinguish pre-and post-replicative states locally remain unknown. Here we reveal that new histones incorporated during DNA replication provide a signature of postreplicative chromatin, read by the human TONSL-MMS22L 1-4 homologous recombination complex. We identify the TONSL ankyrin repeat domain (ARD) as a reader of histone H4 tails unmethylated at K20 (H4K20me0), which are specific to new histones incorporated during DNA replication and mark postreplicative chromatin until the G2/M phase of the cell cycle. Accordingly, TONSL-MMS22L binds new histones H3-H4 both before and after incorporation into nucleosomes, remaining on replicated chromatin until late G2/M. H4K20me0 recognition is required for TONSL-MMS22L binding to chromatin and accumulation at challenged replication forks and DNA lesions. Consequently, TONSL ARD mutants are toxic, compromising genome stability, cell viability and resistance to replication stress. Together, these data reveal a histone-reader-based mechanism for recognizing the post-replicative state, offering a new angle to understand DNA repair with the potential for targeted cancer therapy.
a similar design previously enabled us to solve the structure of an H3-H4 dimer in complex with MCM2 and ASF1 (ref. 7) . We obtained crystals of covalently linked MCM2 HBD-G 4 -TONSL ARD in complex with H3 (57-135) and H4 that diffracted to 2.43 Å resolution, and solved the structure by molecular replacement on the basis of our structure of MCM2 HBD in complex with an H3-H4 tetramer 7 (Fig. 1a, b ; for X-ray statistics, see Extended Data Table 1 ). The structure shows a pair of MCM2 HBDs wrapped around the lateral surface of the H3-H4 tetramer, similar to the MCM2-HBD-H3-H4 complex alone 7, 8 , while two TONSL ARDs interact with each of the H4 tails ( Fig. 1a, b ). The G 4 -linker along with flanking residues formed a 19-residue-long disordered segment that could reach a distance of up to 70 Å. The distance from the observed C terminus of MCM2 HBD to the observed N terminus of TONSL ARD is only 10 Å, indicating that the covalent linkage within the MCM2-HBD-G 4 -TONSL-ARD cassette does not affect the structural integrity of the complex. TONSL ARD forms no intermolecular interactions with the MCM2 HBD, consistent with H3-H4 bridging the interaction of TONSL and MCM2 in cells (Extended Data Fig. 1a ), and it shows only minimal contacts with the core of the H3-H4 tetramer (Fig. 1a, b ). However, the TONSL ARD forms extensive contacts with a segment of the H4 tail (Fig. 1b, c and Extended Data Fig. 1g ) and, consistently, it binds the histone H4 tail, but not the H3 tail, in vitro (Extended Data Fig. 2a ). In addition to defining TONSL binding to soluble histone H3-H4 in complex with MCM2 ( Fig. 1a, b ), this binding mode is also compatible with TONSL binding histone H3-H4 dimers in a co-chaperone complex with MCM2 and ASF1 (ref. 7) as well as recognizing H4 tails in a nucleosome (see models in Extended Data Fig. 2b, c) .
The TONSL ARD consists of four ankyrin repeats, three of which adopt the canonical fold (ANK1-3), while the remaining one is an atypical and capping repeat (ANK4) (Extended Data Fig. 1g ). The TONSL ARD uses its elongated concave surface to form extensive contacts with the H4 tail in an extended β-strand-like conformation ( Fig. 1c and Extended Data Fig. 1g ). Notably, 15 out of 18 residues that constitute the H4-tail-binding surface of TONSL ARD are highly conserved (Extended Data Fig. 2d ). The TONSL ARD targets the H4 tail, spanning residues Lys12 to Arg23 (Fig. 1c-g and Extended Data Fig. 3a, b ) with three consecutive binding channels accommodating Arg17, His18 and Lys20 (Fig. 1d ). These H4 residues are part of a basic region, which can interact with the acidic patch on neighbour nucleosomes 9 in compact chromatin. H4 Arg17 forms two hydrogen bonds with ARD Asn571 and stacks with Tyr572 and Cys608 (Fig. 1c, e ), while H4 His18 penetrates into a pocket lined by four strictly conserved residues (Trp563, Glu568, Asn571 and Asp604) ( Fig. 1c, f) . Substitution of H4 His18 with the larger Trp residue (mutant H18W) disrupts binding with ARD ( Fig. 2a ), underscoring the importance of fitting His18 in the pocket. The H4 Lys20 residue is bound within an acidic surface channel on ARD ( Fig. 1c, d) . The side chain of H4 Lys20 interacts with Met528 and contacts the edge of Trp563 of ARD, while the main-chain atoms of H4 Lys20 packs against Cys561 of ARD (Fig. 1g ). The Nζ atom of H4 Lys20 forms three strong hydrogen bonds (distance <3 Å) with the side chains of strictly conserved residues Glu530, Asp559 and Glu568 of ARD, which engage H4 Lys20 in a triangular arrangement (Fig. 1g ). Consistent with the structural data, histone H4 mutations R17A, H18A and K20A disrupted binding to TONSL in cells ( Fig. 1h ). Likewise, mutation of six conserved TONSL residues lining the H4 Arg17, His18 and Lys20 binding channels disrupted binding to H4 peptides and recombinant histone H3-H4 ( Fig. 1i and Extended Data Fig. 3c ). In vivo, these mutants abrogated binding to soluble histone H3-H4 and, consequentially, also association with ASF1a and ASF1b and MCM2 without affecting MMS22L binding to TONSL 1,2 ( Fig. 1j and Extended Data Fig. 3d ). These mutations did not affect ARD structure, as indicated by circular dichroism (Extended Data Fig. 3e ). Figure 1 | TONSL ARD interacts with the histone H4 tail. a, b, Two different representative views of the overall structure of the TONSL-ARD-MCM2-HBD-H3-H4 tetramer complex. c, Intermolecular interactions between TONSL ARD and the H4 tail. d, The electrostatic potential surface of ARD showing the acidic concave surface binding site for the H4 tail. e-g, Highlights of the intermolecular interactions of H4 Arg17, His18 and Lys20 with ARD. h, Immunoprecipitation (IP) of soluble haemagglutinin (HA)-SNAP-H4 wild type (WT) or mutant transfected into green fluorescent protein (GFP)-TONSL U-2-OS cells. i, ITC of TONSL ARD wild type and mutants with H4 tail peptide. j, Immunoprecipitation of soluble GFP-TONSL wild type or mutant. h, j, Data are representative of three independent experiments. For protein inputs, see Extended Data Fig. 9b 
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Together, this defines TONSL ARD as a recognition module for histone H4 tails, distinct from the GLP/G9A ARDs that bind histone H3 tails mono-or dimethylated at K9 (Extended Data Fig. 4a , b) 10 .
The structure predicts that methylation on H4K20 should break critical hydrogen bonds with the TONSL ARD. Isothermal titration calorimetry (ITC) and H4-tail peptide pull-downs confirmed that H4K20me1/2 is incompatible with TONSL binding ( Fig. 2a-c ). Furthermore, H4K20me2 significantly reduced binding of full-length recombinant TONSL-MMS22L to reconstituted mononucleosomes ( Fig. 2d ). Recently, TONSL ARD with its neighbouring acidic stretch was proposed to bind H3K9me1 (ref. 5 ), but we were unable to detect an interaction between TONSL ARD (with or without the acidic stretch) and H3K9me1 peptides (Extended Data Fig. 4c, d ). Together, our data show that TONSL binds to both free histones and nucleosomes via ARD recognition of H4 tails unmodified at K20 (Figs 1a-j, 2a-e and Extended Data Figs 1b, 2a-c, 3a-d). In line with this, H4K20me2 was not detected on TONSL-bound nucleosomal histones ( Fig. 2f ), while H4K16ac was present (Extended Data Fig. 5a ). H4K16ac stimulated TONSL binding in peptide pull-downs (Fig. 2b, c and Extended Data Fig. 5b ) and slightly enhanced ARD binding in ITC ( Fig. 2a ), but it did not overturn the inhibitory effect of H4K20me2 ( Fig. 2e ). However, H4K16ac is not essential for TONSL binding in vivo, as soluble histone H4 does not carry H4K16ac 11 and depletion of MOF, the major H4K16 acetyltransferase 12 , did not significantly affect TONSL binding to chromatin (Extended Data Fig. 5c, d) . In contrast, depletion of the H4K20 methyltransferase SET8 (also known as PR-SET7) significantly enhanced TONSL binding to chromatin in G1 cells in which H4K20me2 peaks [13] [14] [15] [16] (Fig. 2g and Extended Data Fig. 5e , f). We conclude that TONSL ARD is a histone-reader domain specific for H4 tails unmethylated at K20.
Given that TONSL-MMS22L binds new histones (devoid of H4K20me 11, 17 ) in a pre-deposition complex with ASF1 and MCM2 ( Fig. 1j and Extended Data Fig. 1a ) 1 , TONSL-MMS22L could be loaded onto replicating DNA together with new histones. To test how long after deposition new histones remain unmethylated at H4K20 with the potential to bind TONSL, we extracted H4K20 data from our recent large-scale proteomic study 18 , tracking modifications on new and old recycled histones by nascent chromatin capture (NCC) 19 (Fig. 3a and Extended Data Fig. 6a, b ). In nascent chromatin, new histones were exclusively unmethylated at H4K20 (98% H4K20me0), while old recycled histones were almost fully methylated at H4K20 (me1, 7%; me2, 88%; me3, 2%). Consistent with previous work [13] [14] [15] [16] , our analysis of primary cells (Extended Data Fig. 6c ) and degradation of SET8 in S phase 15, 16 , new histones became methylated in late G2/M, rendering G1 chromatin devoid of H4K20me0 (Fig. 3a ). This identifies H4K20me0 on new histones as a signature of post-replicative chromatin, implying that TONSL-MMS22L can bind H4 tails on new histones at replication forks and sister chromatids until late G2/M. Confirming this prediction, TONSL accumulated on chromatin in S phase, remained chromatin-bound in a population of G2 cells, and was excluded from chromatin in G1 ( Fig. 3b and Extended Data Fig. 6d -f). To discriminate pre-and post-replicative chromatin, we labelled replicating DNA with 5-ethynyldeoxyuridine (EdU; pulse to mark ongoing replication, continuous labelling to identify post-replicative chromatin) and stained pre-replicative chromatin with MCM2 (refs 20, 21), and analysed colocalization with TONSL. TONSL staining was mutually exclusive with MCM2 ( Fig. 3c and Extended Data Fig. 7a ), but colocalized with EdU pulse labelling in very early S phase and with replicated DNA (continuous EdU labelling) throughout S phase ( Fig. 3d and Extended Data Fig. 7b , c). TONSL was present at sites of ongoing DNA replication throughout S phase, but the degree of colocalization declined in mid/ late S phase ( Fig. 3d , left), consistent with TONSL binding to postreplicative chromatin also after fork passage ( Fig. 3d, right) . Mutation of the TONSL ARD abrogated recruitment of TONSL to chromatin, including DNA replication sites (Fig. 3e , f and Extended Data Fig. 7d -g). Together, these data demonstrate that TONSL is recruited to replication forks and post-replicative chromatin via ARD recognition of H4K20me0 on new histones.
Mutation of the TONSL ARD also abrogated chromatin binding and recruitment to replication forks in the presence of replication poisons such as camptothecin (CPT) and hydroxyurea ( Fig. 4a-c ). Furthermore, ARD mutation prevented accumulation of TONSL at site-specific double-strand breaks (DSBs; Fig. 4d and Extended Data Fig. 8a ) and microlaser-generated DNA damage ( Fig. 4e and Extended Data Fig. 8b, c ). Co-staining with cell cycle markers confirmed that TONSL is recruited to DNA repair sites only in S and G2 cells, as expected 2 (Fig. 4e and Extended Data Fig. 8d, e ). We conclude that H4K20me0 binding is required for TONSL accumulation at damaged forks and DNA lesions in post-replicative chromatin. However, this was not due to increased H4K20me0 (Extended Data Fig. 8f ), suggesting that unmasking of H4 tails upon chromatin decompaction 9, 22 and/or interaction with repair factors contribute to TONSL-MMS22L accumulation at repair sites. Consistent with an auxiliary mode of recruitment, MMS22L interaction with RAD51 can stabilize the complex at challenged forks (P. Cejka and M. Peter, personal communication). Our data suggest that this is subsequent to H4K20me0 binding ( Fig. 4a-e ), and we thus next addressed the contribution of H4K20me0 recognition to TONSL-MMS22L function. In complementation analysis, TONSL wild type partially rescued the viability of TONSL-depleted cells in the presence and absence of CPT ( Fig. 4f and Extended Data Fig. 8g , h), whereas TONSL ARD mutants were toxic ( Fig. 4f and Extended Data Fig. 8g , h). In control cells, TONSL ARD mutants also reduced viability, causing G2/M arrest accompanied by replication-associated DNA damage ( Fig. 4g, h ). Furthermore, TONSL ARD mutants titrated MMS22L away from chromatin ( Fig. 4i and Extended Data Fig. 8i ), explaining the dominant-negative phenotype that mimics TONSL-MMS22L depletion [1] [2] [3] [4] . Collectively, this indicates that recognition of H4K20me0 is central to TONSL-MMS22L function in safeguarding genome stability. This study reveals that post-replicative chromatin has a distinct histone modification signature, read by the TONSL-MMS22L effector protein ( Fig. 4j ). This opens a new avenue to understand how DNA repair and other chromosomal transactions can be directly linked to the replication state of a genomic locus. Intriguingly, it is the new histones that make post-replicative chromatin distinct, and in this way H4K20me0 resembles the behaviour of H3K56ac 23 in yeast. Our data indicate that TONSL-MMS22L is delivered to nascent chromatin with new histones via the pre-deposition complex with MCM2 and ASF1 ( Fig. 4j ). We favour the idea that TONSL has a dual function as a histone chaperone 5 and histone reader. Our structural work proposes that TONSL acts in a histone chaperone-like capacity by sequestering the H4 tail to prevent spurious contacts with DNA during H3-H4 deposition. Furthermore, TONSL ARD may counteract chromatin compaction by preventing association of the H4 tail with the H2A-H2B acidic patch on neighbouring nucleosomes. Thus, TONSL changes our perception of a histone chaperone by binding both soluble and nucleosomal histones. In its function as a histone reader, TONSL localizes MMS22L to post-replicative chromatin via H4K20me0 and allows TONSL-MMS22L to accumulate at damaged forks and DNA 
lesions. We envision that H4K20me0 works as an affinity trap, making TONSL-MMS22L readily available to support RAD51 loading during homologous recombination. This provides a new approach and opportunity to understand the role of H4K20 in DNA repair, complementing the well-described role of H4K20me1/2 in recruiting 53BP1 to promote non-homologous end joining in competition with BRCA1-BARD1 (refs 24, 25) . In post-replicative chromatin, H4K20me1/2 on old histones will support 53BP1 recruitment. Whether H4K20me0 on new histones also influences DNA repair pathway choice will be of interest in future investigations. It is notable that the structure of the TONSL ARD, including the histone-binding surface, is highly similar to the ARD of BARD1 (Extended Data Fig. 9a ) 26 , required for BRCA1 tumour suppressor function and homologous recombination 27 . Multiple mutations in the TONSL ARD are reported in cancer (C608G, P557S, E597K; http://cancer.sanger.ac.uk) and the N571 residue, key to histone H4 binding, corresponds to the BARD1 N470S cancer mutation 26, 28 . This highlights the tumour suppressor function of H4K20me0 recognition, and the possibilities it brings for targeted cancer therapy should be explored in the future.
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METHODS
Protein expression and purification.
No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. All proteins used in this study, unless otherwise indicated, were expressed in BL21(DE3)-RIL cell strain (Stratagene). The human TONSL ARD (residues 512-692) and MCM2 HBD (fragments 61-130) were covalently linked through a four-glycine linker (G 4 linker) into one expression cassette. The MCM2 HBD-G 4 -TONSL ARD expression cassette was cloned into a modified RSFDuet-1 vector (Novagen), with an N-terminal His 6 -SUMO tag. The resulting plasmid was co-expressed with plasmid harbouring histone genes H3.3(Δ56) and H4. The expressed protein complex was first purified on an Ni-NTA affinity column. After removing the His 6 -SUMO tag by using Ulp1 (SUMO protease), the protein complex was further purified on HiLoad 16/600 Superdex 200 column (GE Healthcare).
The GST-tagged TONSL ARD and its mutants including E530A, D559A, W563A, E568A, N571A and D604A were cloned into pGEX-6P-1 vector (GE Healthcare). The expressed proteins were first purified using Glutathione Sepharose 4B, then further purified by gel-filtration step. In some case, the GST tag was removed with 3C protease before the gel-filtration step. For purification of GST-H3 tail and GST-H4 tail proteins, the human histones H3 fragment 1-59 and H4 fragment 1-31 were cloned into pGEX-6P-1 vector respectively. The proteins were expressed and purified in the same way.
For production of recombinant full-length TONSL-MMS22L heterodimer, the sequence coding for full-length MMS22L was fused with an MBP tag at the 5′ end and 10× His tag at the 3′ end. The sequence coding for full-length TONSL was fused with a GST tag at the 5′ end. Both MMS22L and TONSL constructs were cloned into a pFastBac1 vector. The complex was expressed in Sf9 cells by co-infection with both recombinant baculoviruses according to manufacturer's recommendation (Invitrogen). The proteins were extracted from Sf9 cells and purified similarly as described previously for Sgs1 (ref. 30) . Briefly, the complex was purified on amylose resin, and MBP and GST tags were subsequently cleaved with PreScission protease. The heterodimer was then further purified using a Ni-NTA affinity resin. Washes were performed with 300 mM NaCl buffer. Crystallization. At first, we tried to crystallize TONSL ARD in complex with a H4 tail or H3-H4 tetramer, but failed even with extensive screening. An additional binding protein may help to stabilize the whole complex and help crystallization. Then we tried to crystallize TONSL ARD in complex with the MCM2 HBD and H3-H4 tetramer. We just got very tiny crystals for this complex, but failed to get big and well-diffracted crystals. We realized that the whole complex of TONSL ARD with MCM2 HBD and H3-H4 tetramer might be destabilized by the harsh crystallization conditions and form a subcomplex, thus hindering the optimization of the crystals. Then we tried to covalently link TONSL ARD and MCM2 HBD into one cassette through different length of glycine linker (G n linker). The G 12 , G 11 , G 10 , G 9 , G 8 , G 7 , G 6 , G 5 and G 4 linkers had been tried and all these cassettes could be crystallized. One of the constructs with a G 4 linker gave well-diffracted crystals.
The G4 linker complex, MCM2-HBD-G 4 -TONSL-ARD cassette-H3.3(Δ56)-H4 complex (herein denoted as TONSL-ARD-MCM2-HBD-H3-H4 tetramer complex) at a concentration of 23 mg ml −1 was crystallized in 0.1 M MES pH 5.6, 7% isopropanol using sitting-drop vapour-diffusion method at 20 °C. All the crystals were soaked in a cryoprotectant made from mother liquor supplemented with 25% glycerol before flash freezing in liquid nitrogen. Structure determination. The data sets for the TONSL-ARD-MCM2-HBD-H3-H4 tetramer complex were collected at 0.979 Å on 24-ID-C/E NE-CAT (Advanced Photo Source, Argonne National Laboratory). All the data sets were processed by using the HKL 2000 program. The initial structure for the TONSL-ARD-MCM2-HBD-H3-H4 tetramer complex was solved by molecular replacement in PHASER 31 with our previous structure of the MCM2-HBD-H3-H4 tetramer complex 7 as a search model and manually refined and built using Coot 32 . The final structure of this complex was refined to 2.43 Å resolution using PHENIX 33 . The Ramachandran plot showed 95.9% favoured and 4.1% allowed. Extended Data Table 1 summarizes the statistics for data collection and structural refinement. Preparation of recombinant modified mononucleosomes. Recombinant human histone proteins were expressed in Escherichia coli BL21(DE3)-RIL cells from pET21b(+) (Novagen) vectors and purified by denaturing gel filtration and ion-exchange chromatography essentially as described 34 . All histone proteins were dialysed into water containing 1 mM dithiothreitol (DTT), lyophilized and stored dry at −80 °C. Modified H4 proteins were generated by native chemical ligation essentially as described for H3 (ref. 35) . Briefly, tail-less H4 Δ1-28 I29C protein was expressed in E. coli BL21(DE3)-RIL cells from pET24b(+) (Novagen) and purified by denaturing gel filtration and reversed-phase chromatography using a ResourceRPC column (GE Healthcare). Purified H4 Δ1-28 I29C was then ligated to N-terminally acetylated H4 1-28 thioester peptides (Almac) and fulllength ligated H4 was separated from unligated H4 Δ1-28 I29C by reversed-phase chromatography via a C18 column (Aquapore RP-300/Perkin Elmer) using a gradient from 35% B to 45% B over 20 column volumes (A: 0.1% TFA in water; B: 90% acetonitrile; 0.1% TFA). Ligated H4 was directly lyophilized and stored dry at −80 °C. Ligated H4 was refolded into octamers together with purified histones H2A, H2B and H3.1 and then assembled into nucleosomes with biotinylated 601-DNA as described 34, 35 . GST pull-downs. For pull-downs of GST-ARD and its mutants including E530A, D559A, W563A, E568A, N571A and D604A with H3-H4, first 25 μl of Glutathione Sepharose 4B beads were suspended with 200 μl of binding buffer (20 mM Tris pH 7.5 and 0.5 M NaCl), and 1 nmol of GST-ARD proteins were added and incubated at 23 °C for 10 min; then 0.5 nmol of pre-purified H3/H4 tetramers were added and incubated for another 1 h; then the beads were washed quickly with five times 1 ml of washing buffer (binding buffer, 1% Triton X-100) before adding 50 μl of sample loading buffer. An aliquot of 20 μl of each sample was analysed with SDS-PAGE. The GST pull-downs of histone tails of GST-H3 1-59 and GST-H4 1-31 with TONSL ARD were performed similarly. Circular dichroism. Circular dichroism spectra were acquired using a Jasco J-815 Circular Dichroism Spectropolarimeter with a 1 mm quartz cuvette. Spectra were recorded for wild-type and mutant TONSL ARD (512-692, 6.25 μM) between 260 nm and 195 nm in KH2PO4/K2HPO4 buffer (25 mM, pH 7.8) with a data pitch of 0.5 nm, bandwidth of 1 nm and with three accumulations at a scanning speed of 50 nm min −1 . In vitro translation and pull-downs with H3-H4 sepharose beads. NHSactivated sepharose 4 Fast-Flow beads (GE Healthcare) were washed with 0.1 M HCl and incubated overnight with 1 μM recombinant histone H3.1-H4 tetramers (New England Biolabs, catalogue number M2509S) or 1 μM recombinant histone H2A-H2B dimers (New England Biolabs, catalogue number M2508S) in Coupling Buffer (0.2 M NaHCO 3 , 0.2 M NaCl). One microgram of pSC-B-TONSL, pEXPR-IBA-105-ASF1A wild-type and pEXPR-IBA-105-ASF1A V94R plasmids was incubated with TnT Quick Coupled Transcription/Translation System (Promega) and 35 S-methionine according to the manufacturer's instructions. Ten microlitres of in vitro translation (IVT) mixture were added to the H3.1-H4, or H2A-H2B, sepharose beads and incubated for 2 h. Beads were washed with 200 mM NaCl, 0.2% NP40 buffer. Beads were boiled in 1× LSB and loaded on a 4-12% Bis-Tris NuPage gel (LifeTechnologies). Proteins were transferred to a 0.2 μm nitrocellulose membrane by overnight wet transfer at 20 V and the membrane was incubated in an autoradiography cassette for 24 h before detection by Phosphor Imager (PerkinElmer). ITC experiments. All the ITC titrations were performed on a Microcal ITC 200 calorimeter at 25 °C or 20 °C. The peptides of H4 (residues 9-25) and its modified peptides K16ac (with acetylation on Lys16), H18W (with His18 mutated to Trp18), H4K20me1 (monomethylation on Lys20) and H4K20me2 (dimethylation on Lys20), and peptide of H3(1-21)K9me1 (monomethylation on Lys9) were all synthesized at Tufts University Core Facility The exothermic heat of the reaction was measured by 17 sequential 2.2 μl injections of the peptides (1.41 mM in buffer 20 mM Tris pH 7.5 and 0.5 M NaCl) into 200 μl of the TONSL ARD solution (145 μM in the same buffer), spaced at intervals of 150 s or 180 s. The data were processed with Microcal Origin software and the curves were fit to a single site binding model. Peptide pull-downs assays. Purified recombinant TONSL ARD (residues 512-692) was stored at 400 μM in 1 M NaCl, 20 mM Tris HCl pH 7.5 at −80 °C. For each pull-down, 400 pmol of the ARD stock (1 μl, 400 μM) was diluted with 99 μl of binding buffer (150 mM NaCl, 50 mM Tris HCl pH 7.5, 5% glycerol, 0.25% NP-40, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 1 mM leupeptin, 1 mM pepstatin). ARD input material was scaled to the number of pull-downs performed. For each pull-down, an H4 peptide (JPT Peptide Technologies GmbH) spanning residues 14-33 (2.5 μl, 250 μM) with a C-terminal biotinoyl-lysine residue or, as control, biotin (2.5 μl, 400 μM) was added to 1.1 ml of binding buffer in addition to 100 μl of the ARD input material and the mixture was incubated overnight rotating at 4 °C. The next day, 25 μl of MyOne Streptavidin C1 beads (Life Technologies) was washed in binding buffer (3 × 500 μl) for each pull-down, removing the final wash from the beads. The ARD/peptide or ARD/biotin mixture was added to an aliquot of pre-washed MyOne Streptavidin C1 beads and incubated with rotation at 4 °C for 3 h. Finally, the beads were washed (2 × 300 μl and 1× 200 μl of 300 mM NaCl, 50 mM Tris HCl pH 7.5, 5% glycerol, 0.25% NP-40, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 1 mM leupeptin, 1 mM pepstatin) and pull-down material was visualized by Coomassie staining after SDS-PAGE separation of proteins on a NuPAGE 4-12% gel.
For pull-downs from cell extracts, MyOne T1 beads were incubated overnight with 1 μg of biotinylated peptides in high salt (HS; 300 mM NaCl, 0.5% NP40, Tris HCl, EDTA, 5% glycerol) buffer and subsequently washed twice with PBS. One milligram of NP40/NaCl extract from HeLa S3 or GFP-TONSL U-2-OS cells was added to the beads and incubated for 2 h rotating at 4 °C. The beads were LETTER RESEARCH then washed five times with HS buffer, 2 min rotating at 4 °C. After washing, the beads were resuspended in 1× LSB and boiled for 10 min. The eluted proteins were loaded on a 4-12% Bis-Tris NuPage gel (Life Technologies). Proteins were then transferred to a 0.2 μm nitrocellulose membrane by overnight wet transfer at 20 V and detected by western blotting. Nucleosome pull-down assay. Modified nucleosomes of H4K20me0 or H4K20me2 were prepared by peptide ligation and stored at 0.1 μg μl −1 (by histone octamer) in 100 mM NaCl, 50 mM Tris HCl pH 7.5 at 4 °C. Full-length TONSL-MMS22L complex was stored at 746 nM in 100 mM NaCl, 50 mM Tris HCl, pH 7.5, 5 mM β-mercaptoethanol, 10% glycerol, 0.5 mM PMSF at −80 °C. Nucleosome pull-downs were performed across two sets of conditions (n = 3 for each condition) in the presence of herring sperm competitor DNA. Condition number 1: Nucleosomes (1 μg by histone octamer) or biotin (0.5 μg) were mixed with TONSL-MMS22L (1.9 pmol) and made up to 30 μl with binding buffer (500 mM NaCl, 50 mM Tris HCl pH 7.5, 20% glycerol, 0.1% NP-40, 1 mM DTT, protease inhibitors and 10 μg ml −1 herring sperm DNA (Sigma)). Inputs of 10 μl were taken before diluting each sample with binding buffer to a final volume of 300 μl and incubating overnight at 4 °C. Pull-downs were performed by adding 20 μl of MyOne Streptavidin C1 beads prewashed and resuspended in 100 μl of binding buffer to each pull-down reaction, incubating at 4 °C for 2 h, washing with 5× 500 μl binding buffer for 2 min at room temperature. Condition number 2: nucleosomes (0.5 μg by histone octamer) or biotin (0.5 μg) were mixed with TONSL-MMS22L (1.3 pmol) and made up to 30 μl with binding buffer (500 mM NaCl, 50 mM Tris HCl pH 7.5, 5% glycerol, 0.5% NP-40, 0.2 mM EDTA, 1 mM DTT, protease inhibitors and 10 μg ml −1 herring sperm DNA (Sigma)). Inputs of 15 μl were taken before diluting each sample with binding buffer to a final volume of 500 μl and incubating overnight at 4 °C. Pull-downs were performed by adding 10 μl of MyOne Streptavidin T1 beads prewashed and resuspended in 100 μl of binding buffer to each pull-down reaction, incubating at 4 °C for 4 h, washing with 5 × 500 μl binding buffer for 2 min at room temperature. Pull-downs were visualized by SYPRO Ruby staining after SDS-PAGE separation of proteins on a NuPAGE 4-12% gel using an ImageQuant LAS 4000 (GE Healthcare). The intensity of stained bands were quantified using ImageJ, TONSL intensity was normalized to the combined intensity of H3, H2A and H2B. Statistical analysis was performed using data from the six independent experiments using the unpaired t-test with equal standard deviations in prism 6. Cell culture, transfection and drug treatment. U-2-OS (gift from J. Bartek), HeLa S3 (gift from P. Nakatami) and TIG-3 (gift from K. Hansen) cells were grown in DMEM (Gibco) containing 10% FBS (Hyclone) and 1% penicillin/ streptomycin and drugs for selection. The construct for siRNA-resistant GFP-TONSL was described 2 and ARD mutations were introduced in this construct by sitedirected mutagenesis. The construct for pBABE-SNAP-HA-H4 plasmid was previously described 36 and H4 tail mutations were introduced in this construct by site-directed mutagenesis. Cells inducible for GFP-TONSL wild type and ARD mutants were generated in Flp-In T-Rex U-2-OS cells (Invitrogen) by transfection of pcDNA5/FRT/TO-GFP-TONSL plasmids with Lipofectamine 2000, according to the manufacturer's protocol, and selection with hygromycin (200 μg ml −1 ). Previously described inducible GFP-TONSL U-2-OS cells 1 were used for Fig. 1h and Fig. 2c , e. U-2-OS Flag-HA-MCM2 wild type and Y81A and Y90A cells were previously described 7 . pBABE-AsiSI-ER-HA 29 was introduced into inducible GFP-TONSL cell lines by lentiviral infection and puromycin selection. All cell lines were authenticated by western blotting and/or immunofluorescence. All cell lines used in this study tested negative for mycoplasma contamination. Expression of GFP-TONSL was induced by addition of 1 μg ml −1 of tetracycline for 24 h. U-2-OS and TIG3 cells were synchronized by a single thymidine block (2 mM) and released into S phase in the presence of 24 μM dCTP. For transient expression of GFP-TONSL or SNAP-HA-H4 (Fig. 1h, j Drug treatment was as follows. CPT: cells were either treated with 1 μM CPT for 3 h (Fig. 4a, i and Extended Data Fig. 8f ) or 20 min (Fig. 4c ), or with 50 nM CPT for 24 h (Fig. 4f) . Hydroxyurea: cells were treated with 3 mM hydroxyurea for 2 h (Fig. 4b ) or 3 h (Extended Data Fig. 8f) . Cell extracts and chromatin solubilisation. For detergent/salt soluble extracts, HeLa S3 and U-2-OS cells were washed with cold PBS, scraped and incubated for 15 min on ice in HS buffer supplemented with trichostatin A (TSA) and protease and phosphatase inhibitors (5 mM sodium fluoride, 10 mM β-glycerolphosphate, 0.2 mM sodium vanadate, 10 μg ml −1 leupeptin, 10 μg ml −1 pepstatin, 0.1 mM PMSF, Sigma). After centrifugation at 16,000g for 15 min at 4 °C, the supernatant was collected. To analyse chromatin-bound complexes, cells were washed twice in cold PBS, scraped and centrifuged at 1,500g for 10 min at 4 °C. The pellet was incubated on ice for 10 min in CSK buffer (10 mM PIPES pH 7, 100 mM NaCl, 300 mM sucrose, 3 mM MgCl 2 )/0.5% Triton X-100, supplemented with TSA and protease and phosphatase inhibitors (5 mM sodium fluoride, 10 mM β-glycerolphosphate, 0.2 mM sodium vanadate, 10 μg ml −1 leupeptin, 10 μg ml −1 pepstatin, 0.1 mM PMSF, Sigma) and subsequently centrifuged at 1,500g for 10 min to collect soluble proteins. For DNaseI or benzonase release of chromatin material, the remaining pellet was resuspended in CSK/0.1% Triton X-100 containing DNase I (1,000 U ml −1 , Roche), or benzonase (2,500 U ml −1 , Millipore), and incubated at 30 °C for 30 min. Solubilized chromatin was then collected by centrifugation at 16,000g for 10 min. Immunoprecipitation from cell extracts. Immunoprecipitation was performed with agarose magnetic GFP-Trap beads (Chromotek), anti-Flag magnetic beads (Sigma) and anti-HA magnetic beads (Life Technologies). Cell extracts were incubated with beads for 2 h at 4 °C rotating. The beads were subsequently washed five times with HS buffer and resuspended in 1× LSB before boiling and SDS-PAGE separation of proteins on a NuPAGE 4-12% gel. Western blotting and antibodies. The following antibodies were used: TONSL (Abcam ab101898), TONSL (Sigma, HPA024679; validated in Extended Data Fig. 6d ), MMS22L 1 Mass spectrometry. Histones from TIG3 fibroblasts were extracted from chromatin as previously described 18 . Protein was resuspended in 50 μl of 100 mM triethylammonium bicarbonate (TEAB; Sigma), pH adjusted with 2 μl of 1.5 M Tris pH 8 and digested for 16 h at 37 °C with 3 μl of 20 ng μl −1 Asp-N (Wako) in 100 mM TEAB. After 15 min centrifugation at 10,000g at 25 °C, the supernatant was placed in a new tube and digestion was repeated for the pellet during 4 h under the conditions described earlier. The digested peptides of both digestions were merged, acidified with 10 μl of 1% TFA and purified using sequential Stagetip C18 and Carbon Toptip (Glygen). Purified peptides were evaporated, resuspended in 15 μl of 0.1% TFA. Injected material was normalized to analyse by liquid chromatography mass spectrometry (LC-MS) the histones corresponding to 9.0 × 10 5 cells. The LC method was used as described elsewhere 18 . The MS was performed in an Orbitrap Classic with similar settings as described previously 18 but with survey scan range at 550-690 m/z and MS2 set in scheduled and targeted data independent mode for the four-time charged ions of the four different methylation states (unmodified, mono-, di-and trimethylated H4K20). Peptides were quantified using the peak area from the corresponding extracted ion chromatograms (±10 p.p.m.). Immunofluorescence, microscopy and laser microirradiation. U-2-OS cells conditional for GFP-TONSL were grown on glass coverslips or 96-well plates and either directly fixed in 4% paraformaldehyde (PFA) for 10 min or washed in CSK, pre-extracted 5 min with cold CSK/0.5% Triton X-100 and rinsed with CSK and PBS before fixation in 4% PFA for 10 min. Coverslips were mounted on glass slides with Mowiol mounting medium (Sigma-Aldrich) containing DAPI. Fluorescence images were collected on a DeltaVision system with a ×40 or ×60 oil immersion objective. For colocalization analysis by deconvolution microscopy, z-stacks were acquired (step of 0.2 μm), deconvolved and analysed by SoftWoRX 5.0.0. Pearson coefficient correlation analysis was performed on single cells using SoftWoRX 5.0.0. Brightness and contrast were adjusted using Adobe Photoshop CS6. For high-content quantitative analysis, fluorescence images were acquired using an Olympus ScanR high-content microscope and processed on the ScanR analysis software. More than 5,000 cells per sample were analysed. Cell cycle phases were gated on DAPI and EdU intensity. Graphs were generated with TIBCO Spotfire software. For microirradiation experiments, cells grown on glass coverslips were fixed in 4% formaldehyde for 15 min, permeabilized with PBS containing 0.2% Triton X-100 for 5 min and incubated with primary antibodies diluted in DMEM for 1 h at room temperature. After staining with secondary antibodies (Alexa Fluor 488, 568 and 647; Life Technologies) for 30 min, coverslips were mounted on glass slides in Vectashield mounting medium (Vector Laboratories) containing LETTER RESEARCH the nuclear stain DAPI. For detection of nucleotide incorporation during DNA replication, an EdU-Plus labelling kit (Life Technologies) was used according to the manufacturer's instructions. Confocal images were acquired on an LSM-780 (Carl Zeiss) mounted on a Zeiss-AxioObserver Z1 equipped with a Plan-Neofluar ×40/1.3 oil immersion objective. Image acquisition and analysis was carried out with LSM-ZEN software. Laser microirradiation of cells was performed essentially as described 38 . ChIP. GFP-TONSL wild type and N571A U-2-OS harbouring the inducible ER-HA-AsiSI endonuclease 29 were treated with 4-OHT and 10 μM DNA-PK inhibitor NU7026 (Millipore) for 4 h to increase homologous recombination 39 . Cells were cross-linked for 10 min in 1% formaldehyde and chromatin was fragmented by sonication using Bioruptor Sonicator (Diagenode). ChIP was performed as previously described 40 with the following modifications: 30 μg of chromatin was immunoprecipitated with 5 μg of anti-GFP (Abcam ab290) and rabbit-IgG. Immunoprecipitated DNA was analysed in duplicate by RT-qPCR. In all cases, γH2A.X induction was verified by immunofluorescence and a sample without 4-OHT was included as a 'no cut' control. Primer pairs for the analysis of DSB-3, DSB-I and DSB-II are described 41 . Primer sequences used for the amplification of a genomic region devoid of DSBs were as follows: noDSB-for: 5′-TGACAAGGACAGGGTCTTCC; noDSB-rev: 5′-CACCGTCCG TTGTATGTCTG. ChIP efficiency was calculated as percentage of input DNA immunoprecipitated. NCC. The NCC protocol 19 was adjusted for adherent U-2-OS cells. CPT (1 μM) was added 5 min before b-dUTP labelling and was included in all steps until fixation. Cells were incubated for 5 min in a hypotonic buffer (50 mM KCl, 10 mM HEPES) containing b-dUTP and resuspended into fresh cell culture medium for an additional 15 min. Cells were fixed 15 min in 1% formaldehyde, rinsed twice in PBS and collected by scraping in cold room. Nuclei were mechanically isolated in sucrose buffer (0.3 M sucrose, 10 mM HEPES-NaOH at pH 7.9, 1% Triton X-100 and 2 mM MgOAc). Chromatin was solubilized by 28 cycles 30 s on, 90 s off in sonication buffer (10 mM HEPES-NaOH at pH 7.9, 100 mM NaCl, 2 mM EDTA at pH 8, 1 mM EGTA at pH 8, 0.2% SDS, 0.1% sodium sarkosyl and 1 mM phenylmethylsulfonylfluoride) using a Bioruptor at 4 °C. Solubilized chromatin was pre-cleared using streptavidin-coated magnetic beads (MyC1 Streptavidin beads) pre-incubated with biotin. b-dUTP labelled chromatin was next purified over night at 4 °C using streptavidin-coated magnetic beads. Beads were washed five times for 2 min in wash buffer (10 mM HEPES-NaOH pH 7.9; 200 mM NaCl; 2 mM EDTA pH 8; 1 mM EGTA pH 8; 0.1% SDS; 1 mM PMSF). Total chromatin (input) and isolated nascent chromatin were boiled for 40 min on beads in LSB 1× (50 mM Tris-HCl pH 6.8, 100 mM DTT, 2% SDS, 8% glycerol, bromophenol blue) and separated by SDS-PAGE for western blotting. Pulse-SILAC-NCC ( Fig. 3a ) was performed as described 18 . Clonogenic assay. U-2-OS inducible for GFP-TONSL ARD wild type and mutant were transfected with siRNA, trypsinized 24 h later and seeded in technical triplicates of 1,000 or 3,000 cells in the presence or absence of tetracycline. After 24 h, cells were washed to remove tetracycline and CPT was added for 24 h as indicated. Cells were then cultured in fresh medium for 12-15 days before fixation and staining with MeOH/Crystal Violet. Colony formation efficiency was determined by manual colony counting or quantification of Crystal Violet staining by ImageJ software and normalized to non-induced control. Each data point represents a technical triplicate of 1,000 or 3,000 seeded cells within each biological replicate. c, Domain structure of TONSL [1] [2] [3] [4] . LRR, leucine-rich repeats; TPR, tetratricopeptide repeats; UBL, ubiquitin-like domain. d, Pull-down of GST-ARD with recombinant histones H3-H4 tetramers. e, f, Pull-down of in vitro-translated full-length TONSL with recombinant histones H3-H4 tetramers (e) or H2A-H2B dimers (f) coupled to NHS-activated sepharose beads (one representative experiment out of three (e) and two (f) is shown). ASF1a wild type and histone-binding mutant (V94R) were included as controls. g, TONSL ARD consists of four ankyrin repeats and uses its elongated concave surface to target the H4 tail spanning residues 12 to 23.
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Extended Data Figure 2 | Models and sequence alignment of TONSL ARD. a, Pull-down assay of recombinant ARD with GST-H3 tail (amino acids 1-59) and GST-H4 tail (amino acids 1-31). b, Modelling of TONSL ARD on the co-chaperone structure of MCM2 HBD and ASF1 in complex with an H3-H4 dimer. When comparing the structure of the TONSL-ARD-MCM2-HBD-H3-H4 tetramer complex with our previous structure of the MCM2-HBD-H3-H4-dimer-ASF1 complex 7 (Protein Data Bank accession 5BNX), the common parts of both structures superimposed well with a small root mean squared deviation (r.m.s.d.) of 0.44 Å. A model of the quinary complex composed of one molecule of each protein, TONSL ARD, MCM2 HBD, ASF1, H3 and H4, was made after superposition. This model shows that TONSL ARD, MCM2 HBD and ASF1 could simultaneously bind an H3-H4 dimer without steric clash. c, Model of TONSL ARD on the structure of the nucleosome. The model was generated by a direct superposition of the H3-H4 tetramer in the structure of the TONSL ARD-MCM2 HBD-H3-H4 tetramer complex onto the H3-H4 tetramer in the nucleosome structure (Protein Data Bank accession 3AV2). There was no adjustment in the conformation of the model and no steric clash in the model. The MCM2 HBD molecules were omitted from the model for clarity. d, Alignment of TONSL ARD (512-692) sequences from Homo sapiens, Mus musculus, Xenopus laevis and Danio rerio. The secondary structures of human TONSL ARD are showed on top of the sequence alignment. Asterisks indicate the highly conserved residues that constitute the H4 tail-binding surface of TONSL ARD and the three strictly conserved acidic residues forming hydrogen bonds with the key residue H4 Lys20 are highlighted with red asterisks. The Lys12-Gly13-Gly14-Ala15 segment of H4 is positioned within a narrow surface channel of the TONSL ARD scaffold. The intermolecular contacts spanning the Lys12-Gly13-Gly14-Ala15 segment of H4 include hydrophobic interactions between residues Gly13, Gly14 and Ala15 of H4 and residues Asn507, Cys508, Trp641, Tyr645 and Leu649 of ARD, as well as hydrogen bonds between the main-chain O of H4 Gly14 and Nε1 of ARD Trp641, and between the main-chain N of H4 Ala15 and Oη of ARD Tyr645 (a; Fig. 1c ). The main-chain O of H4 Lys16 hydrogen bonds with the Nδ2 of ARD Asn571, while the side chain of H4 Lys16 forms contacts with ARD Asn607 and electrostatic interactions with the side chain of ARD Glu597 (Fig. 1c) . The side chain of H4 Arg17 stacks over the side chains of ARD Tyr572 and Cys608, while its Nη1 atom forms two hydrogen bonds with main-chain O and Oδ1 of ARD Asn571 (Fig. 1c, e ). The side chain of H4 H18 penetrates into a pocket lined by four strictly conserved residues (Trp563, Glu568, Asn571 and Asp604) and is positioned over His567 of ARD (Fig. 1c, f) . The side chain of H4 His18 is stacked between Trp563 and Asn571 and forms hydrogen bonds to Glu568 and Asp604 of ARD (Fig. 1f) . The main-chain O of H4 Arg19 forms a hydrogen bond with Nε1 of Trp563 and its side chain forms contacts with Cys561 and Gly595 of ARD (Fig. 1c) . Interactions with the key residue H4 Lys20 are described in the text (Fig. 1g ). The intermolecular contacts spanning the Val21-Leu22-Arg23 segment of H4 include contacts between side chains of H4 Val21 with Tyr560 and Cys561 of ARD (b), while H4 Leu22 interacts with Asp527 and Met528 of ARD. The main-chain N of H4 Arg23 forms a hydrogen bond with the main-chain O of Asp527 of ARD, while the side chain packs against the side chain of Tyr560 of ARD (b). c, Pull-down of recombinant histones H3-H4 with GST-TONSL ARD wild type or indicated mutants. d, Pull-down of pre-purified MCM2 HBD-H3-H4 tetramer complex with GST-TONSL ARD wild type or indicated mutants. e, Circular dichroism analysis of TONSL ARD wild type and the indicated ARD mutants. Both TONSL ARD and GLP ARD use the concave surface to bind their cognate target H4 tail and H3 tail, respectively. TONSL ARD recognizes H4K20me0 mainly through three strong hydrogen bonds with acidic residues Glu530, Asp559 and Glu568, while GLP ARD recognizes H3K9me2 mainly through an aromatic cage forming by residues Trp839, Trp844, Glu847 and Trp877. c, ITC analysis of TONSL ARD binding to H3K9me1 peptide. d, ITC analysis of TONSL acidic stretch and ARD (amino acids 450-692) with H3K9me1 (amino acids 1-21) and H4 (amino acids 9-25) peptides. . Same exposures are shown for input and immunoprecipitation western blots of H3 and H4K16ac. b, TONSL ARD preference for H4K16ac could be mediated by I599 through hydrophobic association with the K16 acetyl group as I599E ARD mutation preferentially reduces binding to H4K16ac peptides as compared to the unmodified H4 tail. Left, pull-down of GFP-TONSL from cell extracts with biotinylated H4 tail peptides. Right, quantification of the western blot, GFP-TONSL binding to the H4K16ac peptide is shown relative to the unmodified peptide. Means with individual data points are shown (n = 2). c, High-content quantitative imaging of TONSL in pre-extracted U-2-OS cells. Plots show total chromatin-bound TONSL and DAPI intensities in cells treated with control or TONSL siRNA, confirming the specificity of TONSL antibody staining. Each dot represents one nucleus. d-f, Analysis of TONSL chromatin-binding in MOF-depleted (d), SET8-depleted (e) and ionizing radiation (IR)-treated cells (f). Chromatin-bound TONSL was quantified by high content imaging of pre-extracted U-2-OS cells stained for endogenous TONSL. Mean TONSL intensity is shown. AU, arbitrary units. d, e, Knockdown efficiency and expected effect on histone modification were confirmed by western blotting (representative of two experiments). e, f, G1 cells were defined by gating on DAPI and EdU intensity. f, TONSL is not recruited to DNA damage in G1 cells, supporting that TONSL accumulation in SET8-depleted cells is due to lack of H4K20me1 and not DNA damage. Cells were irradiated (1.5 Gy) and analysed 1. 
